Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial

Y. Emi, T. Yamanaka, K. Muro, H. Uetake, E. Oki, T. Takahashi, Y. Katayose, K. Yoshida, M. Sakamoto, S. Aishima, K. Ishida, J. Imura, M. Unno, I. Hyodo, N. Tomita, K. Sugihara, Y. Maehara

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii164
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - 2018 Oct 1

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Emi, Y., Yamanaka, T., Muro, K., Uetake, H., Oki, E., Takahashi, T., Katayose, Y., Yoshida, K., Sakamoto, M., Aishima, S., Ishida, K., Imura, J., Unno, M., Hyodo, I., Tomita, N., Sugihara, K., & Maehara, Y. (2018). Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii164. https://doi.org/10.1093/annonc/mdy281.036